Palvella Therapeutics (PVLA) FCF Margin (2014 - 2024)
Palvella Therapeutics (PVLA) reported FCF Margin of 2079.25% for Q1 2024, down 150879.0% year-over-year from N/an in Q2 2023, and down 3192.16% quarter-over-quarter from 63.16% in Q3 2023.
Palvella Therapeutics (PVLA) FCF Margin (2014 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has 11 years of FCF Margin data on file, last reported at 2079.25% in Q1 2024.
- FCF Margin for Q1 2024 came in at 2079.25%, down 150879.0% year-over-year; the trailing twelve-month figure through Sep 2024 was 97.2% (up 22485.0% YoY), and the FY2021 annual result was 30.81%, up 13500.0% from the prior year.
- FCF Margin fell to 2079.25% in Q1 2024 per PVLA's latest filing, from 63.16% in the prior quarter.
- Over five years, FCF Margin peaked at 1168.39% in Q2 2021 and troughed at 3408.53% in Q3 2022.
- A 5-year average of 514.26% and a median of 228.99% in 2020 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin tumbled 289732 bps in 2022, then soared 334537 bps in 2023.
- A 5-year view of FCF Margin shows it stood at 745.6% in 2020, then soared by 68 bps to 239.54% in 2021, then plunged by 1323 bps to 3408.53% in 2022, then jumped by 98 bps to 63.16% in 2023, then tumbled by 3192 bps to 2079.25% in 2024.
- Business Quant data shows PVLA's FCF Margin at 2079.25% in Q1 2024, 63.16% in Q3 2023, and 67.1% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -2,079.25% |
| Sep 30, 2023 | -63.16% |
| Jun 30, 2023 | -67.10% |
| Mar 31, 2023 | -570.45% |
| Sep 30, 2022 | -3,408.53% |
| Jun 30, 2022 | -441.03% |
| Mar 31, 2022 | -208.78% |
| Dec 31, 2021 | -239.54% |
| Sep 30, 2021 | -511.21% |
| Jun 30, 2021 | 1,168.39% |
| Mar 31, 2021 | -93.58% |
| Dec 31, 2020 | -745.60% |
| Sep 30, 2020 | -228.99% |
| Jun 30, 2020 | -96.38% |
| Mar 31, 2020 | -128.63% |
| Dec 31, 2019 | -495.75% |
| Sep 30, 2019 | -85.14% |
| Jun 30, 2019 | -218.79% |
| Mar 31, 2019 | -178.22% |
| Dec 31, 2018 | -1,603.83% |